Targacept, Inc. (TRGT)

[surf1944]

7:50AM Targacept reports EPS in-line (TRGT) 5.21 : Reports Q2 (Jun) GAAP loss of $0.37 per share, in-line with the GAAP Capital IQ Consensus Estimate consensus of ($0.37). No revs were reported

"With recruitment completed this quarter in two ongoing Phase 2b clinical trials and tracking ahead of our initial planning assumptions in a third, we anticipate having three clinical readouts between December 2013 and the middle of 2014. Specifically, we expect to report top-line results from our study of TC-5619 as a treatment for negative symptoms and cognitive dysfunction in schizophrenia in either December 2013 or January 2014, top-line results from our study of TC-5214 as a treatment for overactive bladder in the first half of 2014 and top-line results from our study of TC-1734 in mild to moderate Alzheimer's disease in mid-2014,"